200 related articles for article (PubMed ID: 29895015)
21. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
22. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
23. Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang S; Ngeow J
Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
[TBL] [Abstract][Full Text] [Related]
24. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
25. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.
Vriens MR; Suh I; Moses W; Kebebew E
Thyroid; 2009 Dec; 19(12):1343-9. PubMed ID: 20001717
[TBL] [Abstract][Full Text] [Related]
26. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
27. Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues.
Dağlar-Aday A; Toptaş B; Oztürk T; Seyhan F; Saygili N; Eronat AP; Akadam-Teker B; Yilmaz-Aydoğan H; Aksoy F; Oztürk O
DNA Cell Biol; 2013 Jan; 32(1):13-8. PubMed ID: 23157614
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
29. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.
Finkelstein A; Levy GH; Hui P; Prasad A; Virk R; Chhieng DC; Carling T; Roman SA; Sosa JA; Udelsman R; Theoharis CG; Prasad ML
Histopathology; 2012 Jun; 60(7):1052-9. PubMed ID: 22335197
[TBL] [Abstract][Full Text] [Related]
30. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Tomsic J; He H; de la Chapelle A
N Engl J Med; 2015 Nov; 373(21):2086. PubMed ID: 26581005
[No Abstract] [Full Text] [Related]
31. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Sponziello M; Durante C; Filetti S
N Engl J Med; 2015 Nov; 373(21):2085-6. PubMed ID: 26581004
[No Abstract] [Full Text] [Related]
32. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Zhou EY; Lin Z; Yang Y
N Engl J Med; 2015 Nov; 373(21):2084-5. PubMed ID: 26581003
[No Abstract] [Full Text] [Related]
33. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Zhao X; Li X; Zhang X
N Engl J Med; 2015 Nov; 373(21):2084. PubMed ID: 26581002
[No Abstract] [Full Text] [Related]
34. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Gara SK; Kebebew E
N Engl J Med; 2015 Nov; 373(21):2086-7. PubMed ID: 26581001
[No Abstract] [Full Text] [Related]
35. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
[TBL] [Abstract][Full Text] [Related]
36. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
37. The incidence of familial nonmedullary thyroid cancer in a large case series.
Zivaljevic V; Paunovic I; Diklic A; Krgovic K; Kalezic N; Kazic M; Tatic S; Savic D; Stojanovic D; Perunovic R
Acta Chir Belg; 2008; 108(3):328-32. PubMed ID: 18710108
[TBL] [Abstract][Full Text] [Related]
38. The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian Kindreds.
de Mello LEB; Araujo AN; Alves CX; de Paiva FJP; Brandão-Neto J; Cerutti JM
Clin Endocrinol (Oxf); 2017 Jul; 87(1):113-114. PubMed ID: 28418605
[No Abstract] [Full Text] [Related]
39. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
[TBL] [Abstract][Full Text] [Related]
40. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
